Smith & Nephew (LON:SN) Rating Reiterated by JPMorgan Chase & Co.

Smith & Nephew (LON:SN)‘s stock had its “overweight” rating reissued by equities research analysts at JPMorgan Chase & Co. in a note issued to investors on Thursday, Marketbeat Ratings reports. They currently have a GBX 1,300 ($16.18) target price on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 35.16% from the stock’s previous close.

Several other brokerages have also issued reports on SN. Barclays reiterated an “equal weight” rating and issued a GBX 1,150 ($14.32) target price on shares of Smith & Nephew in a research report on Friday, February 9th. Royal Bank of Canada reiterated an “outperform” rating and issued a GBX 1,500 ($18.67) target price on shares of Smith & Nephew in a research report on Friday, April 5th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of GBX 1,362.50 ($16.96).

Smith & Nephew Stock Down 0.5 %

Shares of LON:SN opened at GBX 961.80 ($11.97) on Thursday. Smith & Nephew has a 52-week low of GBX 887 ($11.04) and a 52-week high of GBX 1,316.75 ($16.39). The firm has a fifty day moving average of GBX 1,045.67 and a 200 day moving average of GBX 1,033.71. The firm has a market capitalization of £8.41 billion, a PE ratio of 4,028.33, a price-to-earnings-growth ratio of 0.46 and a beta of 0.51. The company has a debt-to-equity ratio of 59.11, a quick ratio of 0.84 and a current ratio of 1.77.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.